| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1997;96:3328-3337.)
© 1997 American Heart Association, Inc.
Articles |
From the Department of Geriatric Medicine, Osaka University Medical School, Suita, Osaka, Japan (M.O., H.R., A.O., A.K., K.K., J.H., T.O.); Department of Pathology, Osaka City University Medical School, Osaka, Japan (M.U.); Department of Cardiovascular Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (T.N., A.E.B.); and Second Department of Internal Medicine, Ehime University School of Medicine, Ehime, Japan (K.H.).
Correspondence to Toshio Ogihara, MD, Department of Geriatric Medicine, Osaka University Medical School, 22 Yamadaoka, Suita, Osaka 565, Japan.
Background Balloon injury models in rat have shown enhanced expression of ACE in the developing neointima. However, neointimal lesions in human coronary arteries are complex due to atherosclerosis and different types of wall laceration. This study was designed to investigate whether ACE is present in the neointima of humans, including patients with restenosis after percutaneous transluminal coronary angioplasty (PTCA).
Methods and Results Thirty-seven sites with angioplasty injury, obtained at autopsy, were studied using immunocytochemical techniques. Sites with injury limited to a fibrous plaque and those with injury extending into the media (<2 months after PTCA) showed fibrocellular repair tissue composed mainly of smooth muscle cells that were distinctly positive for ACE. In cellular reactions at the site of injury limited to the atheromatous plaque (<2 months after PTCA), the expression of ACE appeared first in accumulated macrophages; once smooth muscle cells appeared in the repair tissue, they also expressed ACE. At a later stage (3 months after PTCA), the number of cells with ACE expression decreased markedly; from 7 months on, ACE was no longer expressed within the repair tissue. Basically, there were no differences with regard to ACE expression during the healing process after PTCA between segments with and those without angiographic evidence of restenosis.
Conclusions These results show that PTCA injury in humans results in upregulation of ACE at sites of active repair and, therefore, ACE could play an important role as one of the mediators of the healing process after PTCA.
Key Words: angioplasty angiotensin atherosclerosis coronary disease immunohistochemistry
This article has been cited by other articles:
![]() |
K. Ohtani, K. Egashira, Y. Ihara, K. Nakano, K. Funakoshi, G. Zhao, M. Sata, and K. Sunagawa Angiotensin II Type 1 Receptor Blockade Attenuates In-Stent Restenosis by Inhibiting Inflammation and Progenitor Cells Hypertension, October 1, 2006; 48(4): 664 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Shiraya, K. Miwa, M. Aoki, T. Miyake, M. Oishi, K. Kataoka, S. Ohgi, T. Ogihara, Y. Kaneda, and R. Morishita Hypertension Accelerated Experimental Abdominal Aortic Aneurysm Through Upregulation of Nuclear Factor {kappa}B and Ets Hypertension, October 1, 2006; 48(4): 628 - 636. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Paul, A. Poyan Mehr, and R. Kreutz Physiology of local Renin-Angiotensin systems. Physiol Rev, July 1, 2006; 86(3): 747 - 803. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Ribichini, F. Pugno, V. Ferrero, G. Bussolati, M. Feola, P. Russo, C. Di Mario, A. Colombo, and C. Vassanelli Cellular Immunostaining of Angiotensin-Converting Enzyme in Human Coronary Atherosclerotic Plaques J. Am. Coll. Cardiol., March 21, 2006; 47(6): 1143 - 1149. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Kumar and P. H Winocour Review: Dual blockade of the renin angiotensin system in diabetes -- rationale and risks The British Journal of Diabetes & Vascular Disease, September 1, 2005; 5(5): 266 - 271. [Abstract] [PDF] |
||||
![]() |
F. Ribichini, V. Ferrero, W. Wijns, G. Matullo, A. Piazza, E. Uslenghi, J. L. Zhuo, F. A.O. Mendelsohn, and M. Ohishi Can ACE Inhibitors Promote Detrimental Vascular Effects After Percutaneous Injury? * Response Hypertension, October 1, 2002; e6(4): . [Full Text] [PDF] |
||||
![]() |
D. A Sica Review: The practical aspects of combination therapy with angiotensin receptor blockers and angiotensin-converting enzyme inhibitors Journal of Renin-Angiotensin-Aldosterone System, June 1, 2002; 3(2): 66 - 71. [Abstract] [PDF] |
||||
![]() |
J. L. Zhuo, F. A.O. Mendelsohn, and M. Ohishi Perindopril Alters Vascular Angiotensin-Converting Enzyme, AT1 Receptor, and Nitric Oxide Synthase Expression in Patients With Coronary Heart Disease Hypertension, February 1, 2002; 39(2): 634 - 638. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Nishimoto, S. Takai, S. Kim, D. Jin, A. Yuda, M. Sakaguchi, M. Yamada, Y. Sawada, K. Kondo, K. Asada, et al. Significance of Chymase-Dependent Angiotensin II-Forming Pathway in the Development of Vascular Proliferation Circulation, September 11, 2001; 104(11): 1274 - 1279. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Hoshida, J. Kato, M. Nishino, Y. Egami, T. Takeda, M. Kawabata, J. Tanouchi, Y. Yamada, and T. Kamada Increased Angiotensin-Converting Enzyme Activity in Coronary Artery Specimens From Patients With Acute Coronary Syndrome Circulation, February 6, 2001; 103(5): 630 - 633. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Matsumoto, R. Morishita, A. Moriguchi, N. Tomita, M. Aoki, H. Sakonjo, K. Matsumoto, T. Nakamura, J. Higaki, and T. Ogihara Inhibition of Neointima by Angiotensin-Converting Enzyme Inhibitor in Porcine Coronary Artery Balloon-Injury Model Hypertension, February 1, 2001; 37(2): 270 - 274. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. E. Gordon, B. S. Davis, C. J. Carlson, and F. W. Booth ANG II is required for optimal overload-induced skeletal muscle hypertrophy Am J Physiol Endocrinol Metab, January 1, 2001; 280(1): E150 - E159. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hosono, M. Ueda, S. Suehiro, Y. Sasaki, T. Shibata, K. Hattori, and H. Kinoshita Neointimal formation at the sites of anastomosis of the internal thoracic artery grafts after coronary artery bypass grafting in human subjects: An immunohistochemical analysis J. Thorac. Cardiovasc. Surg., August 1, 2000; 120(2): 319 - 328. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. B Strawn, R. H Dean, and C. M Ferrario Novel mechanisms linking angiotensin II and early atherogenesis Journal of Renin-Angiotensin-Aldosterone System, March 1, 2000; 1(1): 11 - 17. [PDF] |
||||
![]() |
F. Ribichini, F. Pugno, V. Ferrero, G. Bussolati, G. Melissano, R. Chiesa, C. Di Mario, and A. Colombo Angiotensin-Converting Enzyme Tissue Activity in the Diffuse In-Stent Restenotic Plaque Circulation, January 18, 2000; 101 (2): e33 - e35. [Full Text] [PDF] |
||||
![]() |
A. Okamura, M. Ohishi, H. Rakugi, T. Katsuya, Y. Yanagitani, S. Takiuchi, Y. Taniyama, K. Moriguchi, H. Ito, Y. Higashino, et al. Pharmacogenetic Analysis of the Effect of Angiotensin-Converting Enzyme Inhibitor on Restenosis After Percutaneous Transluminal Coronary Angioplasty Angiology, October 1, 1999; 50(10): 811 - 822. [Abstract] [PDF] |
||||
![]() |
S. Nakamura, A. Moriguchi, R. Morishita, K. Yamada, T. Nishii, N. Tomita, M. Ohishi, Y. Kaneda, J. Higaki, and T. Ogihara Activation of the Brain Angiotensin System by In Vivo Human Angiotensin-Converting Enzyme Gene Transfer in Rats Hypertension, August 1, 1999; 34(2): 302 - 308. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Yanagitani, H. Rakugi, A. Okamura, K. Moriguchi, S. Takiuchi, M. Ohishi, K. Suzuki, J. Higaki, and T. Ogihara Angiotensin II Type 1 Receptor–Mediated Peroxide Production in Human Macrophages Hypertension, January 1, 1999; 33(1): 335 - 339. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Zhuo, M. Ohishi, and F. A. O. Mendelsohn Roles of AT1 and AT2 Receptors in the Hypertensive Ren-2 Gene Transgenic Rat Kidney Hypertension, January 1, 1999; 33(1): 347 - 353. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |